Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report published on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

CARA opened at $4.75 on Wednesday. The business has a 50 day simple moving average of $4.02 and a 200-day simple moving average of $3.83. The stock has a market capitalization of $21.70 million, a P/E ratio of -2.71 and a beta of 0.51. Cara Therapeutics has a 12 month low of $2.71 and a 12 month high of $13.80.

Institutional Trading of Cara Therapeutics

Several large investors have recently modified their holdings of the business. FMR LLC lifted its position in shares of Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Cara Therapeutics during the third quarter valued at approximately $29,000. Finally, Disciplined Growth Investors Inc. MN grew its stake in Cara Therapeutics by 6.6% in the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 120,660 shares during the period. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.